header
Image from OpenLibrary

Preparation of mucosal inactivated vaccine for ND and H9N2 AI viruses / Heba Mohamed Elsayed Elnagger ; Supervised Hussein Ali Hussein , Mohamed Sayed Madkour

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Heba Mohamed Elsayed Elnagger , 2017Description: 121 P. : charts ; 25cmOther title:
  • H9N2 تحضير لقاح مخاطى مثبط لفيروسى النيوكاسل و انفلونزا الطيور [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Veterinary Medicine - Department of Virology Summary: The aim of the present study was to develop a mucosal inactivated vaccines for ND and H9N2 viruses to protect against these viruses at sites of infections through mucosal immunity. We prepared two new formulations for mucosal bivalent inactivated vaccine formulations for newcastle and avian influenza (H9N2) based on the use of nanoparticles and polymer adjuvants. The prepared vaccines were delivered via intranasal and spray routes of administration in SPF chickens. Cell mediated and humeral immune responses were measured as well as challenge trial was carried out. In addition ISA71 water in oil was also evaluated. Results showed that the use of spray route as vaccination delivery method of polymer and nanoparticles MontanideTM adjuvants revealed that it enhanced the cell mediated immune response as indicated by phagocytic activity, gamma interferon and interleukin 6 responses and induce protection against challenge with Newcastle and Avian Influenza (H9N2) viruses. Results after challenge with velogenic NDV genotype VIId NDV, the protection % for groups received IMS1313 vaccine was 40%. Groups received the Gel 01 vaccine revealed 50% and 60% for intranasal and spray route; respectively. On the other hand, the chickens vaccinated with ISA71 vaccine demonstrated 100% protection. No shedding was detected in samples from Groups which received Gel 01 and ISA71 vaccines in all interval days after challenge with H9N2. In conclusion, the results of the present study demonstrate the potentiality of polymer compared to nanoparticles adjuvants when used via spray route. Mass application of such vaccines will be add value to improve the vaccination strategies against NDV and AIV viruses.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.10.17.Ph.D.2017.He.P (Browse shelf(Opens below)) Not for loan 01010110074122000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.10.17.Ph.D.2017.He.P (Browse shelf(Opens below)) 74122.CD Not for loan 01020110074122000

Thesis (Ph.D.) - Cairo University - Faculty of Veterinary Medicine - Department of Virology

The aim of the present study was to develop a mucosal inactivated vaccines for ND and H9N2 viruses to protect against these viruses at sites of infections through mucosal immunity. We prepared two new formulations for mucosal bivalent inactivated vaccine formulations for newcastle and avian influenza (H9N2) based on the use of nanoparticles and polymer adjuvants. The prepared vaccines were delivered via intranasal and spray routes of administration in SPF chickens. Cell mediated and humeral immune responses were measured as well as challenge trial was carried out. In addition ISA71 water in oil was also evaluated. Results showed that the use of spray route as vaccination delivery method of polymer and nanoparticles MontanideTM adjuvants revealed that it enhanced the cell mediated immune response as indicated by phagocytic activity, gamma interferon and interleukin 6 responses and induce protection against challenge with Newcastle and Avian Influenza (H9N2) viruses. Results after challenge with velogenic NDV genotype VIId NDV, the protection % for groups received IMS1313 vaccine was 40%. Groups received the Gel 01 vaccine revealed 50% and 60% for intranasal and spray route; respectively. On the other hand, the chickens vaccinated with ISA71 vaccine demonstrated 100% protection. No shedding was detected in samples from Groups which received Gel 01 and ISA71 vaccines in all interval days after challenge with H9N2. In conclusion, the results of the present study demonstrate the potentiality of polymer compared to nanoparticles adjuvants when used via spray route. Mass application of such vaccines will be add value to improve the vaccination strategies against NDV and AIV viruses.

Issued also as CD

There are no comments on this title.

to post a comment.